Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitro

N Etminan*,1,5 C Peters1,2,5, D Lakbir2, E Bünemann3, V Böürger2, MC Sabel1, D Hänggi1, H-J Steiger1, W Stummer4 and RV Sorg2

1Department of Neurosurgery, Heinrich-Heine-University Hospital, Bldg. 13.71, Moorenstrasse 5, Düsseldorf 40225, Germany; 2Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich-Heine-University Hospital, Moorenstrasse 5, Düsseldorf 40225, Germany; 3Department of Dermatology, Heinrich-Heine-University Hospital, Moorenstrasse 5, Düsseldorf 40225, Germany; 4Department of Neurosurgery, University of Münster, Albert-Schweitzer-Strasse 33, Münster 48149, Germany

BACKGROUND: T-cell responses contribute to the anti-tumoural effect of photodynamic therapy (PDT). For such responses to occur, dendritic cells (DCs) have to migrate to the tumour, take up tumour antigens and respond to danger signals with maturation, before they engage in T-cell activation. Here, we have studied the effect of 5-aminolevulinic acid (ALA)-mediated PDT on DCs in vitro in a human spheroid model of glioblastoma (GB).

METHODS: Spheroids of the GB cell lines U87 and U251 were treated with ALA/PDT, and effects on attraction, uptake of tumour antigens and maturation of DCs were studied. To block heat-shock protein-70 (HSP-70) on the spheroids, neutralising antibodies were used.

RESULTS: 5-Aminolevulinic acid/PDT-treated GB spheroids attracted DCs that acquired tumour antigens from the spheroids effectively. Moreover, co-culture with ALA/PDT-treated spheroids induced DC maturation as indicated by the upregulation of CD83 and co-stimulatory molecules as well as increased T-cell stimulatory activity of the DCs. Heat-shock protein-70 was upregulated on the spheroids after ALA/PDT treatment. Uptake of tumour antigens and DC maturation induced by the ALA/PDT-treated spheroids were inhibited when HSP-70 was blocked.

CONCLUSION: ALA/PDT treatment of glioma spheroids promotes the three initial steps of the afferent phase of adaptive immunity, which is at least partially mediated by HSP-70.

British Journal of Cancer (2011) 105, 961–969. doi:10.1038/bjc.2011.327 www.bjcancer.com

Keywords: 5-aminolevulinic acid; glioma; photodynamic therapy; dendritic cells; HSP-70

Photodynamic therapy (PDT) is a promising approach in the treatment of various tumours (Dolmans et al, 2003). It is based on the preferential accumulation of a photosensitiser in tumour cells and its excitation with light of a defined wavelength. This excitation initiates a photochemical reaction, resulting in the generation of reactive oxygen species within the tumour cells, for example, singlet oxygen, which cause secondary reactions leading to cell death. Photodynamic therapy results either in apoptosis or necrosis of the tumour cells, depending on the photosensitiser and its intracellular localisation, the cell type, oxygen concentration and PDT dose (Castano et al, 2006).

Although PDT-induced phototoxicity kills tumour cells directly, it is well established that there is also an immunological component to the anti-tumoural effect of PDT (Dolmans et al, 2003; Castano et al, 2006). Reduced efficacy of PDT in immunodeficient mice lacking T cells (Korbelik et al, 1996; Hendrzak-Henion et al, 1999; Preise et al, 2009) indicates a pivotal role of T cells. This is further supported by adoptive transfer experiments (Korbelik and Dougherty, 1999; Preise et al, 2009) and lymphocyte-depletion studies (Hendrzak-Henion et al, 1999; Korbelik and Cecic, 1999; Korbelik and Dougherty, 1999), identifying CD8+ cytotoxic T cells as main effectors. However, for such T-cell responses to occur, tumour antigens have first to be taken up by immature dendritic cells (DCs), danger signals have to induce DC maturation, associated with migration of DCs to local lymph nodes and mature DCs in the lymph nodes have to present the tumour antigens to the specific T cells in the context of adhesion, co-stimulatory and other accessory molecules, either directly or after antigen transfer to other DCs (Ueno et al, 2010).

Photodynamic therapy generates an altered tumour microenvironment that appears to promote this afferent phase of adaptive immunity. Tumour cells undergoing necrosis or apoptosis release tumour antigens that can be taken up by DCs (Green et al, 2009). Moreover, immediately after PDT an inflammatory response develops providing danger signals such as pro-inflammatory cytokines. Together with stress proteins like heat-shock proteins (HSP) induced on the surface or released by the tumour cells after treatment that appears to promote this afferent phase of adaptive immunity.
Translational Therapeutics

ALA/PDT on attraction, tumour antigen uptake and maturation of gliomas on the afferent phase of adaptive immunity. Therefore, mechanisms in GB and about the influence of ALA/PDT treatment of protoporphyrin IX, probably mainly due to low ferrochelatase activity (Krammer and Plaetzer, 2008; Teng et al, 2011). If exposed to a wave length of 400 nm, this preferential accumulation of protoporphyrin IX in tumour cells allows their intraoperative activity (Krammer and Plaetzer, 2008; Teng et al, 2011). After 3 years, most patients have relapsed and median survival after relapse is 6.2 months (Stupp et al, 2009). As a consequence, PDT in combination with highly selective photosensitisers, for example, 5-aminolevulinic acid (ALA), is gaining clinical interest for the treatment of patients with GB (Beck et al, 2007; Eljamel et al, 2008; Stummer et al, 2008).

5-Aminolevulinic acid is an intermediate of the haem biosynthesis pathway. In many tumour cells including GB, an excess of the exogenous pro-drug ALA results in the accumulation of protoporphyrin IX, probably mainly due to low ferrochelatase activity (Krammer and Plaetzer, 2008; Teng et al, 2011). If exposed to a wave length of 400 nm, this preferential accumulation of protoporphyrin IX in tumour cells allows their intraoperative identification during fluorescence-guided surgery. In GB, the extent of the resection can be increased significantly, leading to improved progression-free survival of patients (Stummer et al, 2006). When exposed to 635 nm, protoporphyrin IX acts as a potent photosensitiser, which can be exploited for intraoperative as well as stereotactic PDT of GB (Beck et al, 2007; Eljamel et al, 2008; Stummer et al, 2008). In a patient with non-resectable, recurrent GB, who had failed multimodal therapy, stereotactic ALA/PDT resulted in a long-sustaining response (Stummer et al, 2006). Moreover, in a recent phase III study combining ALA- and photofrin-mediated fluorescence-guided resection and PDT, a benefit in survival and time to progression was observed (Eljamel et al, 2008). The phototoxic damage caused by ALA/PDT, however, can be increased significantly, leading to improved preoperative survival of patients (Stummer et al, 2006). When exposed to 635 nm, protoporphyrin IX acts as a potent photosensitiser, which can be exploited for intraoperative as well as stereotactic PDT of GB (Beck et al, 2007; Eljamel et al, 2008; Stummer et al, 2008). In a patient with non-resectable, recurrent GB, who had failed multimodal therapy, stereotactic ALA/PDT resulted in a long-sustaining response (Stummer et al, 2006). Moreover, in a recent phase III study combining ALA- and photofrin-mediated fluorescence-guided resection and PDT, a benefit in survival and time to progression was observed (Eljamel et al, 2008). The phototoxic damage caused by ALA/PDT, however, can be increased significantly, leading to improved preoperative survival of patients (Stummer et al, 2006).

Flow cytometry and monoclonal antibodies

To assess uptake of tumour material, treated and untreated spheroids were labelled with CFSE (Molecular Probes/Invitrogen, Karlsruhe, Germany) and co-cultured with immature DCs. After 16 h of co-culture, DCs were labelled with anti-HLA-DR monoclonal antibody (mAb) and uptake of tumour material by HLA-DR+ DCs was determined by flow cytometry on a FACSCanto using the DIVA software (BD Biosciences, Heidelberg, Germany), identifying antigen uptake by the appearance of HLA-DR/CFSE double-positive DCs within living cells identified based on forward- vs side-scatter characteristics. At least 10 000 living cells were acquired in each experiment. To study the effect of blocking 2 mM L-Gln (all from Lonza) at 37 °C and 5% CO2 in tissue culture flasks (Greiner, Nürtlingen, Germany). To induce glioma spheroid formation, cells were harvested, and 2 x 10^6 cells were plated in 20 ml suspended DMEM medium without phenol red in agar-coated 775 tissue culture flasks. After 3 to 4 days of culture, spheroids with a diameter of 200 μm had formed.

**Materials and Methods**

**Generation of GB spheroids**

The human GB cell lines U87 and U251 were maintained in DMEM medium (Lonza, Verviers, Belgium) supplemented with 10% foetal calf serum, 100 U/ml penicillin, 100 μg/ml streptomycin and 25% horse serum, 1000 U/ml penicillin, 100 μg/ml streptomycin and 1 penicillin, 100 U/ml streptomycin, 100 U/ml bovine pituitary extract, 0.04 mg/ml hydrocortisone, 0.01 mg/ml insulin, and 0.1 mg/ml transferrin. Media were changed every 3 days and cultures were continued for 3 days before analysis. To study the effect of blocking HSP-70 on glioma spheroids, the spheroids were pre-incubated with goat-anti-human HSP-70 polyclonal IgG antibody (1:20; Santa Cruz, Heidelberg, Germany) before the co-cultures were initiated.

**Generation of DCs**

Buffy coats were obtained from healthy individuals after informed consent. CD14+ monocytes were immunoselected from PBMcs using LS separation columns on a VarioMACS (Miltenyi Biotec, Bergisch Gladbach, Germany) as described (Rapp et al, 2006). Differentiation and maturation of DCs from monocytes was performed following a protocol adapted from Zhou and co-workers (Zhou and Tedder, 1996; Rapp et al, 2006). Briefly, CD14+ monocytes were cultured in 24-well plates (Greiner) at 1 x 10^6 cells per ml and 2 ml per well in serum-free CellGroDC medium (Cellgenix, Freiburg, Germany) supplemented with 1000 U/ml GM-CSF (Leukine, Berlex, Richmond, CA, USA) and 1000 U/ml IL-4 (Cellgenix). After 3 days, half of the medium was replaced by fresh medium containing cytokines. Immature CD14+ DCs were harvested after 6 days of culture. To induce DC maturation, 1000 U/ml TNFz (Cellgenix), GM-CSF and IL-4 were added to immature DCs on day 6, and cultures were continued for 3 days. The influence of GB spheroids on DC maturation was studied in co-cultures. In all, 25 untreated spheroids or spheroids that had been treated with ALA (ALA-only) or exposure to laser light (laser-only) or both (ALA/PDT) were added to the DC cultures on day 6 and cultures continued for 3 days before analysis. To study the effect of blocking HSP-70 on glioma spheroids, the spheroids were pre-incubated with goat-anti-human HSP-70 polyclonal IgG antibody (1:20; Santa Cruz, Heidelberg, Germany) before the co-cultures were initiated.

**Materials and Methods**

**Generation of GB spheroids**

The human GB cell lines U87 and U251 were maintained in DMEM medium (Lonza, Verviers, Belgium) supplemented with 10% foetal calf serum, 100 U/ml penicillin, 100 μg/ml streptomycin and 25% horse serum, 1000 U/ml penicillin, 100 μg/ml streptomycin, 100 U/ml bovine pituitary extract, 0.04 mg/ml hydrocortisone, 0.01 mg/ml insulin, and 0.1 mg/ml transferrin. Media were changed every 3 days and cultures were continued for 3 days before analysis. To study the effect of blocking HSP-70 on glioma spheroids, the spheroids were pre-incubated with goat-anti-human HSP-70 polyclonal IgG antibody (1:20; Santa Cruz, Heidelberg, Germany) before the co-cultures were initiated.
HSP-70 on antigen uptake, the spheroids were pre-incubated with goat-anti-human HSP-70 polyclonal IgG antibody before assessing antigen uptake by flow cytometry.

The following mAbs were used for immunostainings: PE-conjugated CD14 (RM052), CD83 (HB15a) and FITC-conjugated CD80 (MAB104) and CD83 (HB15a) specific mAb from Beckman-Coulter (Krefeld, Germany); PE-conjugated HLA-DR (G46-6) and FITC-conjugated CD40 (SC3) and CD86 (FUN-1) specific mAb from BD Biosciences; and PE-conjugated goat polyclonal IgG specific for HSP-70 (K-20) from Santa Cruz.

Migration assay
To assess migration of immature DCs towards spheroids, a transwell assay was used. Spheroids, CellGroDC medium (negative control) and medium containing 40 ng ml⁻¹ CCL3 (positive control; R&D Systems, Wiesbaden, Germany) were transferred into a 24-well plate (500 µl per well). Transwell inserts (8 µm pore size; Greiner) were coated with 100 µl fibronectin (5 µg ml⁻¹; Sigma/Aldrich, Seelze, Germany) for 1 h at room temperature, placed in the 24-well plate containing the migration targets and immature DCs in CellGroDC medium (50 000 DCs/200 µl) for 1 h at 37 °C. CO2, cells were fixed with methanol and migrated DCs stained with 10 µl FITC; and 40 µl PI at 37 °C and 5% CO2, cells were washed with methanol and migrated DCs stained with an ImageJ software (http://rsweb.nih.gov/ij/).

Statistics
If not stated otherwise, all data are presented as mean ± s.e.m. Statistical analysis was performed with the Graph Pad Prism Software Version 5.01 (GraphPad, San Diego, CA, USA). Statistical significance was evaluated with the Student’s t-test or the two-way ANOVA test.

RESULTS
ALA/PDT-treated spheroids attract immature DCs
Attraction of immature DCs to ALA/PDT-treated spheroids or control spheroids (untreated, ALA-only-treated, laser-light-only-treated) was assessed in a transwell migration assay (Figure 1). The immature DCs showed no or only weak attraction of immature DCs.

Enhanced uptake of tumour material by immature DCs after ALA/PDT treatment of spheroids
To determine uptake of tumour material from glioma spheroids, CFSE-labelled ALA/PDT-treated spheroids or control spheroids were co-cultured with immature DCs for 16 h, and antigen uptake by the DCs was subsequently quantified by flow cytometry. Pre-treatment of spheroids with ALA/PDT resulted in a significant uptake of tumour material by the DCs from U251 (Figures 2A–C; A: 1314.0 vs 297.6, B: 794.3 ± 172.1 vs 164.3 ± 33.1, C: 794.3 ± 172.1 vs 164.3 ± 33.1) compared to medium controls.

ALA/PDT-treated spheroids induce maturation of DCs
To study the influence of glioma spheroids on DC maturation, immature DCs were co-cultured for 3 days in the presence or absence of ALA/PDT-treated or control spheroids. Subsequently, the expression of the maturation marker CD83 and the co-stimulatory molecules CD40, CD80 and CD86 was analysed.
Cultures with TNFα for 3 days served as positive controls for DC maturation. In the presence of ALA/PDT-treated spheroids, a significant proportion of DCs had matured as evident by an increased frequency of CD83+ cells compared to control cultures in the absence of maturation stimuli (U251, 43.5 ± 12.6 vs 4.5 ± 1.9% CD83+; n = 4, P = 0.0223; U87, 46.1 ± 10.4 vs 3.1 ± 1.4% CD83+; n = 5, P = 0.0034). In contrast, co-culture of immature DCs with control spheroids (untreated, ALA-only- or laser-light-only-treated) did not induce DC maturation (Figure 3A). Similar results were obtained when the expression of the co-stimulatory molecules was analysed. Only after co-culture with ALA/PDT-treated spheroids, but not with the control spheroids, a significant upregulation of CD40, CD80 and CD86 on the DCs compared to control cultures without maturation stimuli was observed (Figure 3B).

Functional activity of DCs matured in the presence or absence of ALA/PDT-treated or untreated spheroids of the cell lines U251 (Figure 4A) or U87 (Figure 4B) was evaluated in an allogeneic mixed leukocyte reaction. Control immature DCs that were neither exposed to spheroids nor to the maturation-inducing TNFα revealed allostimulatory activity, which was comparable to that of DCs co-cultured with untreated spheroids (P > 0.05 (ANOVA); n = 3), with a trend towards reduced allostimulatory activity of the DCs after co-culture with untreated U251 spheroids (P = 0.0644).

When maturation of DCs was induced with TNFα, allostimulatory activity increased significantly compared to the immature DCs (P = 0.0094 for Figure 4A and P = 0.0004 for Figure 4B (ANOVA); n = 3). Increased allostimulatory activity of DCs was also observed after co-culture with ALA/PDT-treated U251 (P = 0.0014 (ANOVA); n = 3) or U87 spheroids (P < 0.0001 (ANOVA); n = 3) compared to co-cultures with untreated spheroids. Co-cultures of DCs with ALA/PDT-treated U87 spheroids reached allostimulatory activity levels similar to TNFα-matured DCs (P > 0.05 (ANOVA); n = 3). For U251 spheroids, ALA/PDT treatment could compensate the reduction of allostimulatory activity observed after co-culture of immature DCs with untreated spheroids and activity increased to levels comparable to the immature DCs (P > 0.05 (ANOVA); n = 3). Thus, for both cell lines an increased functional activity of DCs after co-culture with ALA/PDT-treated spheroids was observed, which is consistent with the induction of DC maturation.

**ALA/PDT treatment of glioma spheroids induces HSP-70, which mediates uptake of tumour antigens and maturation of DCs**

Heat-shock protein-70 has been shown to be upregulated on the surface of mouse squamous cell carcinoma cells after photofrin-mediated PDT and to contribute to immune activation (Korbek
et al., 2005; Korbelik and Sun, 2006). Therefore, a possible involvement of HSP-70 in the effects of ALA/PDT on DCs was addressed.

When HSP-70 surface expression was compared for untreated and ALA/PDT-treated U251 and U87 spheroids, a clear upregulation of surface HSP-70 was evident for the treated spheroids.
Heat-shock protein-70 was absent or expressed at only very low levels on the untreated spheroids (Figure 5A, representative results of three independent experiments).

Blocking of HSP-70 on the ALA/PDT-treated spheroids before assessing uptake of tumour material from the spheroids inhibited tumour antigen uptake significantly (U251, 1456.0 ± 73.7 vs 769.7 ± 46.3 MFI FITC; n = 3, P = 0.0014; U87, 1295.0 ± 95.3 vs 679.0 ± 180.5 MFI FITC; n = 3, P = 0.0393; Figure 5B). Moreover, blocking of HSP-70 also inhibited the DC maturation induced in co-cultures of immature DCs and ALA/PDT-treated U251 or U87 spheroids as indicated by a significant decrease in the frequency of CD83⁺ mature DCs (U251, 40.0 ± 4.5 vs 6.7 ± 1.3% CD83⁺; n = 3, P = 0.002; U87, 25.6 ± 2.5 vs 3.8 ± 0.6% CD83⁺; n = 3, P = 0.0006; Figures 5C, D). In contrast, no reduction in the frequency of mature CD83⁺ DCs was observed when ALA/PDT-treated U251 or U87 spheroids were treated with a control immunoglobulin before co-culture with the immature DCs (Figure 5D).

**DISCUSSION**

There is clear evidence for an immunological component in the anti-tumoural effect of PDT from extracranial tumours (Castano et al, 2006). Immediately after PDT, there is immigration of neutrophils into the tumour (Krosi et al, 1995), and depletion of neutrophils before treatment abrogates the curative effect (de Vree et al, 1996; Korbelik and Cecic, 1999), suggesting an important contribution of innate immunity to the efficacy of PDT. However, results from immunodeficient NOD/SCID mice, lacking B and T cells, and nude mice, lacking T cells only (Canti et al, 1994; Korbelik et al, 1996; Hendrzak-Henion et al, 1999; Preise et al, 2009), indicate an essential role of adaptive T-cell immunity as well, with CD8⁺ cytotoxic T cells as main effectors and a supportive role for CD4⁺ T-helper cells (Hendrzak-Henion et al, 1999; Korbelik and Cecic, 1999; Korbelik and Dougherty, 1999; Preise et al, 2009). Moreover, Mroz et al (2010) identified antigen-specific cytotoxic T cells after benzoporphyrin-derivative/PDT treatment in a CT26.CL25 colon carcinoma model. Furthermore, a recent case report suggests that an immune response contributes to tumour eradication also in humans: CD4⁺ and CD8⁺ T-cell infiltrates have been observed in lesions after Fotolon-mediated PDT of recurrent angiosarcoma, which underwent remission after therapy (Thong et al, 2007).

For such effector T-cell responses to occur, immature DCs have to migrate to the tumour, take-up tumour antigens and respond to local danger signals with maturation, before they will engage in T-cell activation in the draining lymph nodes in the afferent phase.
of cellular adaptive immunity (Ueno et al., 2010). Consistent with this view, Preise et al (2009) reported higher recurrence rates of CT26 colon carcinomas treated with WST11-mediated PDT after DC depletion. When the migration of human immature DCs to glioma spheroids was analysed here, ALA/PDT treatment resulted in significantly increased attraction of the DCs towards the tumour cells. Moreover, the immature DCs took up tumour material from the ALA/PDT-treated spheroids efficiently, whereas they did not from untreated tumour spheroids or spheroids that had only been treated with ALA or laser light alone. Thus, two of the initial steps of the afferent phase of adaptive tumour immunity are promoted by ALA/PDT.

The efficiency of PDT-treated tumour cells as vaccines for induction of anti-tumoural immunity has been shown for SCVII squamous cell carcinoma, Lewis lung carcinoma, EMT6 mammary carcinoma, P815 mastocytoma and C6 rat glioma models using photofrin, benzo[ghi]perylene derivative or haematoxylin as photosensitisers (Gollnick et al, 2002; Korbelik and Sun, 2006; Shixiang et al, 2010). This implies that the PDT-treated cancer cell vaccines are recognised and taken up by the DCs. Indeed, Korbelik and Sun (2006) reported that the vaccine cells were intermixed with DC 1h after injection, suggesting active migration of DC towards the tumour vaccines in vivo. Evidence for uptake of tumour antigens after PDT also comes from the intratumoral injection of DCs following PDT treatment: improved survival of animals and induction of tumour-specific immunity indicate that the DCs have taken up tumour antigens (Jalili et al, 2004; Saji et al, 2006; Sur et al, 2008). Furthermore, when immature DCs were co-cultured with CT26 tumour cells subjected to photofrin/PDT, enhanced uptake of tumour material by the DCs was detected (Jalili et al, 2004).

Attraction of DCs and uptake of tumour antigens alone, however, are not sufficient for the initiation of an immune response, but may result in immunological tolerance (Green et al., 2009; Tisch, 2010; Ueno et al., 2010). An activating danger signal inducing DC maturation is required. Here, ALA/PDT-treated spheroids provided such a maturation-inducing stimulus. When immature DCs were co-cultured with ALA/PDT-treated spheroids, maturation of DCs was induced as indicated by the induction of the marker for mature DCs, CD83 and upregulation of the co-stimulatory molecules CD40, CD80 (B7.1) and CD86 (B7.2). Importantly, these changes in the expression of immunorelevant molecules were associated with an increased T-cell stimulatory activity of the DCs. From the efficacy of PDT-generated vaccines, which was superior compared to vaccines generated using UV or ionising irradiation (Gollnick et al, 2002; Korbelik and Sun, 2006), and from the efficacy of intratumorally injected DCs following PDT (Jalili et al, 2004; Saji et al, 2006; Sur et al, 2008) as well as from increased frequencies in IFN-γ-secreting cells and the generation of tumour-specific CTL in the treated animals reported by others, it can be concluded that DCs have undergone maturation owing to PDT treatment of the tumour cells in these studies as well. This has been confirmed by in vitro analyses showing induction of MHC class II molecules, CD80, CD86 and IL-12 in co-culture experiments of DCs and PDT-treated mouse tumour cells by Jalili et al (2002; Jalili et al, 2004) or DCs and acid-eluted material from PDT-treated C6 rat glioma cells (Shixiang et al, 2010).

The factors and mechanisms involved in promoting attraction, antigen uptake and maturation of DCs following PDT are not well understood. Depending on the photosensitiser, its location within the cell and dose, the cell type and oxygen concentration, PDT results in apoptotic or necrotic cell death (Castano et al, 2006). The protocol used in this study mainly induced apoptosis as determined by TUNEL staining (Etminan et al., 2011). Induction of apoptosis after ALA/PDT treatment of GB cells has also been reported by Inoue et al (2007). Apoptotic cells release several chemotactic factors, including nucleotides, lipids and chemokines, which may attract DCs. Changes in surface molecules on apoptotic cells, for example, expression of calreticulin or HSP-70 and -90, allow recognition and engulfment of apoptotic bodies (Green et al., 2009; Žitvogel et al., 2010). Although apoptotic cells have been suggested to fail to induce DC maturation and to be associated with induction of immunological tolerance, this also appears to depend on the pre-apoptotic conditioning, for example, stress, of the cells together with the sequence of the events rather than solely on apoptotic vs necrotic cell death. The release of inflammatory mediators, damage-associated molecular patterns and alarmins like the pro-inflammatory cytokines HMGBl and IL-1x during apoptosis may contribute to DC maturation (Green et al., 2009; Žitvogel et al., 2010). It is well established that PDT results in the upregulation of inflammatory mediators, including IL-1β, IL-6, TNF-α, prostaglandins and various HSPs, and glucose-regulated proteins (Gollnick et al, 1997; Dolmans et al, 2003; Jalili et al, 2004; Korbelik et al, 2005; Castano et al, 2006). For the glioma spheroids, we observed upregulation of HSP-70 surface expression, and when HSP-70 was blocked by antibodies, uptake of tumour antigens as well as DC maturation induced by the ALA/PDT-treated spheroids was almost completely inhibited. Korbelik et al (2005) and Korbelik and Sun (2006) also suggested a pivotal role of surface HSP-70 in PDT-induced immune activation: inhibitors to HSP-70, Toll-like receptors 2 and 4 or specific inhibition of NF-κB blocked macrophage activation and TNF-α release induced by photofrin-mediated PDT of SCCVII mouse squamous cell carcinoma cells. Thus, surface expression of HSP-70 appears to be a major DC maturation-inducing stimulus after PDT in mice as well as in humans. Whether other factors, including pro-inflammatory cytokines and HSP or glucose-regulated proteins, have been reported to be upregulated on tumour cells in response to PDT (Gollnick et al, 1997; Dolmans et al, 2003; Jalili et al, 2004; Korbelik et al, 2005; Castano et al, 2006), are also upregulated and contribute to attraction, antigen uptake and maturation of DCs by ALA/PDT-treated GB cells is currently unknown.

For human GB, the immunological consequences of ALA/PDT have not been analysed so far. In this study, we could show that ALA/PDT treatment of GB spheroids attracts DCs and promotes uptake of tumour antigens as well as DC maturation in vitro. However, our study holds limitations: although the spheroid model may mimic microtumours more closely than monolayer cultures (Sutherland, 1988; Hirschhäuser et al, 2010), differences between the established cell lines used here and primary tumour cells in vitro or the tumour, including its vasculature and stroma in vivo, may result in a different effect of ALA/PDT. In addition, it remains to be elucidated whether the above-described effects on DCs result in cross-presentation of tumour antigens and induction of cytotoxic T-cell-mediated anti-tumoural immunity in vivo. Therefore, further studies evaluating the effect of ALA/PDT on primary tumour cells as well as in vivo studies are needed to document efficacy of PDT in GB and the contribution of an anti-tumoural immune response to it.

In summary, like in extracerebral tissues, ALA/PDT may not only kill GB cells directly due to its phototoxic effect, but may also result in the induction of anti-tumoural immunity, mediated by induction of cytotoxic T-cell-mediated anti-tumoural immunity in vivo. Therefore, further studies evaluating the effect of ALA/PDT on primary tumour cells as well as in vivo studies are needed to document efficacy of PDT in GB and the contribution of an anti-tumoural immune response to it.

ACKNOWLEDGEMENTS

This work has been supported by a grant from the Research Committee of the Medical Faculty of the Heinrich-Heine-University, Düsseldorf, Germany. Dr Etminan is grateful for support by the German Federation of Neurosurgery (DGNC). We thank Heike Löfler and Brigitte Senger for excellent technical assistance.
REFERENCES

Beck TJ, Kreth FW, Beyer W, Mehrkens JH, Obermeier A, Stepp H, Stummer W, Baumgartner R (2007) Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX. Lasers Surg Med 39: 386 – 393

Canti G, Lattuada D, Nicolini A, Taroni P, Valerini G, Cubeddu R (1994) Antitumor immunity induced by photodynamic therapy with aluminum disulfonated phthalocyanine and laser light. Anticancer Drugs 5: 443 – 447

Canetta AP, Mroz P, Hamblin MR (2006) Photodynamic therapy and antitumor immunity. Nat Rev Cancer 6: 535 – 545
de Vree WJ, Essers MC, de Bruijn HS, Star WM, Koster JF, Sluiter W (1996) Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. Cancer Res 56: 2908 – 2911

Dolmans DE, Fukumura D, Jain RK (2003) Photodynamic therapy for cancer. Nat Rev Cancer 3: 380 – 387

Eljamel MS, Goodman C, Moseley H (2008) ALA and photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre phase III randomised controlled trial. Lasers Med Sci 23: 361 – 367

Etminan N, Peters C, Ficnar J, Anlasik S, Bu¨nemann E, Slotty P, Eljamel MS, Goodman C, Moseley H (2008) ALA and photofrin multiforme: a single centre phase III randomised controlled trial. Lasers Med Sci 23: 361 – 367

Korbelik M, Cecic I (2005) Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res 65: 1018 – 1026

Krammer B, Platterz K (2008) ALA and its clinical impact, from bench to bedside. Photochem Photobiol Sci 7: 283 – 289

Kros G, Korbelik M, Dougherty GJ (1995) Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy. Br J Cancer 71: 549 – 555

Mroz P, Szokalska A, Wu MX, Hamblin MR (2010) Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response. PLOS One 5: e15194

Ozlow B, Hundef CT, Stocker S, Bise K, Reulen HJ, Stummer W (2002) Photoirradiation therapy of experimental malignant gloma with 5-aminolevulinic acid. J Neurosurg 97: 970 – 976

Preise D, Oren R, Gilnert I, Kalchenko V, Jung S, Scherz A, Salomon Y (2009) Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity. Cancer Immunol Immunother 58: 71 – 84

Rapp M, Ozcan Z, Steiger HJ, Wernert P, Sabel MC, Sorg RV (2006) Cellular immunity of patients with malignant gloma: prerequisites for dendritic cell vaccination immunotherapy. J Neurosurg 105: 41 – 50

Saji H, Song W, Furumoto K, Kato H, Engleman EG (2006) Systemic antitumor activity of photodynamic therapy-mediated dendritic cells in combination with local photodynamic therapy. Clin Cancer Res 12: 2568 – 2574

Shixiang Y, Xi S, Junliang L, Shanyi Z, Kai W, Fangcheng L (2010) Antitumor efficacy of a photodynamic therapy-generated dendritic cell glioma vaccine. Med Oncol; doi: 10.1007/s12032-010-9713-y

Sorg RV, Andres S, Kögler G, Fischer J, Wernert P (2001) Phenotypic and functional comparison of monocytes from cord blood and granulocyte colony-stimulating factor-mobilized apheresis products. Exp Hematol 29: 1299 – 1294

Steel CD, Haltio SM, Ciavarra RP (2009) Peripheral dendritic cells are essential for both the innate and adaptive antiviral immune responses in the central nervous system. Virology 387: 117 – 126

Stummer W, Beck T, Beyer W, Mehrkens JH, Obermeier A, Etminan N, Stepp H, Tonn JC, Baumgartner R, Herrns J, Kreth FW (2008) Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report. J Neurosurg 87: 103 – 109

Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant gloma: a randomised controlled multicentre phase III trial. Lancet Oncol 7: 392 – 401

Thong PS, Ong KW, Goh NS, Kho KW, Manivasager V, Bhuvaneswari R, Olivo M, Soo KC (2007) Photodynamic therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma. Lancet Oncol 8: 950 – 952

Tisch R (2010) Immunogenic versus tolerogenic dendritic cells: a matter of maturation. Int Rev Immunol 29: 111 – 118

Ueno H, Schmitt N, Klechevsky E, Pedroza-Gonzalez A, Matsui T, Zurawski G, Oh S, Fay J, Pascual V, Sanchereau J, Palucka K (2010) Harnessing human dendritic cell subsets for medicine. Immunol Rev 234: 199 – 212

Bjornsson OI, Landin LA, Hunsaker JS, Cizikowski JR, Romeijn JS, Prospero RJ, Herrman J, Lyle SR, Caputo M, Greco MA, et al. (2009) A randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 2459 – 2466

Sur BW, Nguyen P, Sun CH, Tromberg BJ, Nelson EL (2008) Immuno-phototherapy using PDT combined with rapid intratumoral dendritic cell injection. Photochem Photobiol 84: 1257 – 1264
Van Gool S, Maes W, Ardon H, Verschuere T, Van Cauter S, De Vleeschouwer S (2009) Dendritic cell therapy of high-grade gliomas. *Brain Pathol* 19: 694–712

Zhou LJ, Tedder TF (1996) CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. *Proc Natl Acad Sci USA* 93: 2588–2592

Zitvogel L, Kepp O, Kroemer G (2010) Decoding cell death signals in inflammation and immunity. *Cell* 140: 798–804

Zozulya AL, Reinke E, Baiu DC, Karman J, Sandor M, Fabry Z (2007) Dendritic cell transmigration through brain microvessel endothelium is regulated by MIP-1alpha chemokine and matrix metalloproteinases. *J Immunol* 178: 520–529

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.